RE: Nice buys30 Apr 2024 07:16
Alderley Park, UK, 30 April 2024 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, targeted therapeutics for the treatment of fibrotic disease and cancer today announces that it has been notified that Peter Collum, Chief Financial Officer and Claire Solk, General Counsel, both of whom are classed as persons discharging managerial responsibility ("PDMR's") under EU Regulation 596/2014 as it forms part of domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 have on 26 and 29 April 2024 acquired 267,108 Redx ordinary shares. Peeps have got shafted and directors have bought on the cheap